论文部分内容阅读
【目的】探讨米非司酮预防子宫肌瘤患者术后复发的疗效。【方法】选择子宫肌瘤患者136例，按照术后是否用药分为两组，每组68例，观察组术后每晚服用米非司酮12．5mg，1次／天，连续服用1个月为一个疗程，共3个疗程；对照组术后不给予米非司酮或其他激素类药物治疗。比较两组术后1、12个月时血清卵泡刺激素（FSH）、雌二醇（E2）及孕酮水平和术后12个月复发率，记录观察组患者服药期间的不良反应。【结果】观察组术后12个月内的总复发率为2．9％（2／68），显著低于对照组14．7％（10／68），差异有统计学意义（P＜0．05）；观察组术后1个月FSH、E2及孕酮激素水平显著低于对照组（P＜0．05），术后12个月3项激素水平比较无显著性差异（P＞0．05），观察组服药期间仅部分患者出现轻微不良反应，在停药后均恢复正常。【结论】米非司酮可降低子宫肌瘤术后的复发率，且无明显不良反应。“,”[Objective] To explore the recurrence‐preventing efficacies of mifepristone after myomectomy .[Methods] A total of 136 patients with myoma of uterus were recruited and divided randomly into observation and control groups according to whether or not there was an addition of postoperative medication ( n = 68 each) .The control group underwent hysteromyoma resection alone .And the observation group received 3 postoperative one‐month courses of mifepristone per night 12 .5 mg .At 3 and 6 months post‐operation ,the se‐rum levels of hemoglobin (Hb) ,follicle‐stimulating hormone (FSH) ,estradiol (E2 ) and progesterone were compared for two groups .And recurrence rates and adverse reactions were recorded .[Results] The overall 12‐month recurrence rate was significantly lower in observation group than that in control group (2 .9% vs 14 .7% ) .And the difference had statistical significance ( P < 0 .05) .As compared with control group ,the levels of FSH ,E2 and progesterone were significantly lower in observation group at 1 month ( P 0 .05) .During medica‐tion ,mild adverse reactions occurred in some patients and recovered after drug withdrawal .[Conclusion]Mifepristone can reduce and prevent a recurrence of uterine fibroids after myomectomy .